Dyne Therapeutics
127 hedge funds and large institutions have $629M invested in Dyne Therapeutics in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 53 increasing their positions, 31 reducing their positions, and 6 closing their positions.
3,420% more call options, than puts
Call options by funds: $176K | Put options by funds: $5K
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
71% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 31
12% more funds holding
Funds holding: 113 → 127 (+14)
10% more capital invested
Capital invested by funds: $573M → $629M (+$55.4M)
2.06% more ownership
Funds ownership: 94.9% → 96.96% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$21.4M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$9M |
| 3 |
Goldman Sachs
New York
|
+$8.55M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$8.11M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$5.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.06M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$5.99M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.84M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$4.54M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$2.69M |
DYN Hedge Fund Activity: Q1 2023 in Review
127 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q1 2023, worth a combined $629M — up 9.7% from $573M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new DYN positions and 6 closed out — a net gain of 14 holders — while 53 added to existing stakes and 31 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $21.4M. The largest seller was Point72 Asset Management, cutting an estimated $6.06M.
- 127 institutional investors held Dyne Therapeutics (DYN) as of Q1 2023, up from 113 in Q4 2022.
- Funds reported $629M of Dyne Therapeutics stock for Q1 2023, up 9.7% quarter-over-quarter.
- 20 funds opened new Dyne Therapeutics positions in Q1 2023 and 6 closed out, a net change of +14 holders.
- The largest Dyne Therapeutics buyer in Q1 2023 was TCG Crossover Management, an estimated $21.4M added.
- The largest Dyne Therapeutics seller in Q1 2023 was Point72 Asset Management, an estimated $6.06M sold.
Based on aggregated 13F filings for Q1 2023.